Does Insurance Cover Ozempic, Wegovy, Zepbound & Mounjaro? (2026 Guide + Appeal Letter)
Whether your plan pays for a GLP-1 comes down to one question first: is it prescribed for type 2 diabetes or for weight loss? Diabetes coverage is close to standard. Weight-loss coverage depends on your employer, your plan's pharmacy benefit manager and, for Medicare, a new $50 program with strict BMI rules. Here's how each type of coverage works in 2026, what prior authorization asks for, and how to appeal a denial, with a letter builder to get you started.
Medically reviewed Medically reviewed by Sabrina Griswold, Pharm.D. — NPI 1821451063 · Last updated 2026-11-10
- For type 2 diabetes (Ozempic, Mounjaro): covered by almost every plan, including Medicare Part D and Connecticut Medicaid, usually with prior authorization.
- For weight loss (Wegovy, Zepbound, Foundayo): commercial plans cover it only if your employer or plan includes weight-loss drugs. Medicare covers it for $50 a month through the GLP-1 Bridge (July 2026–December 2027) if you meet BMI rules. Connecticut HUSKY doesn't cover weight loss.
- Denied? You usually have 180 days to appeal, and then an independent external review. Use the letter builder below to start.
Coverage at a glance, by reason and plan type
The reason on your prescription matters more than the brand. Each GLP-1 is approved for specific uses, and plans cover those uses under different rules:
| Prescribed for | Job-based or Marketplace plan | Medicare | HUSKY (CT Medicaid) | TRICARE |
|---|---|---|---|---|
| Type 2 diabetes Ozempic, Mounjaro, Ozempic tablets, Rybelsus | Usually covered, with prior authorization | Part D covers; $2,100 yearly cap in 2026 | Covered, usually with prior authorization | Covered |
| Weight loss Wegovy, Zepbound, Foundayo | Only if your plan includes weight-loss drugs | $50 Bridge, if BMI rules are met | Not covered since mid-2025 | Prime and Select with prior authorization; not TRICARE For Life |
| Sleep apnea Zepbound | Depends on plan; a separate approved use | Part D can cover | Ask us to check | Ask us to check |
| Heart-risk reduction Wegovy, with heart disease | Depends on plan; a separate approved use | Part D can cover | Ask us to check | Ask us to check |
For commercial plans, the insurer usually isn't the one deciding whether weight-loss drugs are covered. Your employer chooses whether to include them.
Aetna, Cigna, UnitedHealthcare, Blue Cross, TRICARE
Two layers decide your coverage: whether your plan includes the drug's use at all (for weight loss, usually your employer's choice) and which GLP-1 the pharmacy benefit manager prefers. Here's what's known about each:
Aetna
- Weight loss
- Only on plans that include it. Many Aetna plans use the CVS Caremark formulary, which preferred Wegovy from July 2025 and added Zepbound back as a preferred option on October 1, 2026 (plus Foundayo from June 1, 2026).
- Diabetes
- Ozempic and Mounjaro generally covered with prior authorization
Cigna
- Weight loss
- Only on plans that include it; Express Scripts sets the preferred drug and prior authorization criteria
- Diabetes
- Commonly covered with prior authorization
UnitedHealthcare
- Weight loss
- Only on plans that include it; Optum Rx sets the preferred drug and criteria
- Diabetes
- Commonly covered with prior authorization
Blue Cross Blue Shield
- In Connecticut
- The Blue plan is Anthem; rules vary by employer and by individual plan
- Diabetes
- Generally covered with prior authorization
TRICARE
- Prime and Select
- Wegovy and Zepbound covered for weight loss with an approved prior authorization
- TRICARE For Life
- Weight-loss coverage ended August 31, 2025; diabetes still covered. Medicare's $50 Bridge may be an option with Part D.
Kaiser Permanente
- Coverage
- Kaiser doesn't operate in Connecticut. Where it does, weight-loss coverage depends on the region and the plan.
- Diabetes
- Typically covered on its formulary
The fastest way to know for sure: call the member services number on your card and ask three questions:
- "Does my plan cover weight-loss medications, or exclude them?"If excluded, an appeal rarely works. Your employer's benefits team is the place to ask for a change.
- "Is [drug] on my formulary, and is it the preferred one?"If another GLP-1 is preferred, you may have to try it first (step therapy).
- "What are the prior authorization criteria?"Write down the BMI cutoff, required conditions and any required diet program, and give them to your prescriber.
Medicare: Part D and the $50 GLP-1 Bridge
Part D covers GLP-1s for their approved medical uses: Ozempic and Mounjaro for type 2 diabetes, Wegovy for heart-risk reduction or MASH, and Zepbound for sleep apnea. In 2026 your out-of-pocket drug costs are capped at $2,100 for the year.
The Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers GLP-1s for weight loss alone, which Part D was never allowed to do. It covers Wegovy (pen or pill), the Zepbound KwikPen and Foundayo. Eligibility, from CMS:
| BMI when you started the GLP-1 | Plus at least one of these |
|---|---|
| 35 or higher | No other condition needed |
| 30 or higher | Heart failure with preserved ejection fraction · uncontrolled high blood pressure (above 140/90 despite two blood pressure medicines) · chronic kidney disease stage 3a or higher |
| 27 or higher | Prediabetes · a previous heart attack · a previous stroke · symptomatic peripheral artery disease |
- You must be 18 or older with Part D or a Medicare Advantage plan with drug coverage, and use the drug with ongoing diet and activity changes.
- $50 a month, flat. The Part D deductible doesn't apply, the $50 doesn't count toward your $2,100 cap, and Extra Help (LIS) doesn't reduce it.
- Your prescriber requests approval from CMS's central processor, not from your Part D plan. CMS encourages electronic submission.
- Not for type 2 diabetes, sleep apnea or MASH. Those stay under regular Part D coverage.
- Manufacturer savings cards can't be used with any Medicare coverage.
What prior authorization asks for
Prior authorization (PA) is your plan's check that the drug fits its criteria before it pays. Your prescriber submits it; the pharmacy usually finds out it's needed when the claim is rejected. Plans commonly ask for:
For weight loss
- BMI and weight on the date treatment started, from a clinic visit
- Weight-related conditions: high blood pressure, prediabetes or diabetes, high cholesterol, sleep apnea, heart disease
- A diet, exercise or behavioral program you've followed, often for several months
- For renewals: weight lost since starting, usually as a percentage
For type 2 diabetes
- A type 2 diabetes diagnosis code
- Recent A1c
- Metformin tried first, or a reason you can't take it
- That you're not also taking another GLP-1
The most common gap is paperwork, not eligibility: a BMI that wasn't recorded at the start, no documented diet program, or the wrong diagnosis code. Ask your prescriber's office to include all of it on the first submission. When a PA is approved, ask when it expires: most approvals have an end date and need renewing, often with proof of results.
If you're denied: how to appeal
Denial letter arrives. Read the reason: missing information, step therapy, a different preferred drug, or a plan exclusion.
File an internal appeal with your plan, with a letter from you and, ideally, a letter of medical necessity from your prescriber.
Plan decides for a drug you haven't received yet (faster if urgent).
Request an external review by an independent reviewer if the plan still says no. Standard decision within 45 days, expedited within 72 hours.
Fill in what you know and get a draft appeal letter to print or copy. Nothing you type leaves this page. Give the draft to your prescriber: a letter of medical necessity signed by them carries the most weight.
- Match the letter to the denial reason. For step therapy, document the drug you already tried and why it failed or wasn't tolerated. For "not preferred," explain why the preferred drug isn't right for you.
- A plan exclusion is the hardest case. If your plan simply excludes weight-loss drugs, appeals rarely succeed. Ask HR whether the benefit can be added at open enrollment, and look at self-pay options.
- Keep copies of everything you send, and note the date and the name of anyone you speak with.
If it's simply not covered
- Self-pay prices are far below list. The Wegovy pill starts at $149 a month, the Wegovy pen at $199, and Zepbound at $299. Every route is in our GLP-1 price guide.
- Commercial insurance that doesn't cover it? Some manufacturer cards still help: Mounjaro can be as low as $499 a month. See the GLP-1 savings card guide.
- Deciding between drugs? Compare results and costs in Ozempic vs. Mounjaro vs. Wegovy vs. Zepbound.
Call Arrow Pharmacy at (860) 522-9289 before your prescriber sends the prescription. We'll run a test claim, tell you whether prior authorization is needed and which GLP-1 your plan prefers, and apply the manufacturer savings card if you qualify. Already filling elsewhere? We can transfer it.
Frequently asked questions
Does insurance cover Ozempic?
For type 2 diabetes, almost always, usually with prior authorization and sometimes after a trial of metformin. That includes commercial plans, Medicare Part D and Connecticut Medicaid (HUSKY). For weight loss without diabetes, Ozempic isn't approved, so plans rarely cover it; the approved semaglutide for weight loss is Wegovy.
Does Medicare cover Zepbound or Wegovy for weight loss?
Through the Medicare GLP-1 Bridge, yes, from July 1, 2026 to December 31, 2027: Wegovy (pen or pill), the Zepbound KwikPen and Foundayo cost $50 a month if you qualify. You need a BMI of 35 or more, or 30 or more with heart failure with preserved ejection fraction, uncontrolled high blood pressure or stage 3a+ kidney disease, or 27 or more with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease. Your prescriber requests approval from CMS.
Does Medicare cover Ozempic or Mounjaro?
Yes, for type 2 diabetes. Medicare Part D plans cover them, usually with prior authorization, and in 2026 your yearly out-of-pocket drug costs are capped at $2,100. Manufacturer $25 savings cards can't be used with Medicare.
Does Medicaid cover Ozempic or Wegovy?
Medicaid covers GLP-1s for type 2 diabetes in every state, usually with prior authorization. Coverage for weight loss is each state's choice. Connecticut's HUSKY stopped covering GLP-1s prescribed only for weight loss in mid-2025 because of cost; it still covers them for type 2 diabetes and certain other approved uses.
Does Aetna cover Zepbound or Wegovy?
It depends on whether your employer's plan includes weight-loss drugs. Aetna is owned by CVS Health, and many Aetna plans use CVS Caremark's formulary, which made Wegovy the preferred weight-loss GLP-1 in July 2025 and added Zepbound back as a preferred option on October 1, 2026. Call the number on your card to confirm your plan's formulary and prior authorization rules.
Does Cigna or UnitedHealthcare cover Zepbound and Wegovy?
Both cover them only on plans that include weight-loss medication, which is usually the employer's decision. Cigna plans typically use Express Scripts and UnitedHealthcare plans Optum Rx as the pharmacy benefit manager, and each sets which GLP-1 is preferred and what prior authorization requires. For type 2 diabetes, Ozempic and Mounjaro are commonly covered with prior authorization.
Does Blue Cross Blue Shield cover Ozempic, Wegovy or Zepbound?
Blue Cross Blue Shield is a network of independent companies, so the answer varies by state and plan. In Connecticut the Blue plan is Anthem. Diabetes use is generally covered with prior authorization; weight-loss coverage depends on whether your employer or individual plan includes it.
Does TRICARE cover Wegovy and Zepbound?
TRICARE Prime and Select cover weight-loss GLP-1s such as Wegovy and Zepbound with an approved prior authorization. TRICARE For Life, the plan for Medicare-eligible retirees, stopped covering GLP-1s for weight loss on August 31, 2025; GLP-1s for type 2 diabetes are still covered. TRICARE For Life members may qualify for Medicare's $50 GLP-1 Bridge if they have Part D.
How do I get Zepbound covered by insurance?
First confirm your plan covers weight-loss drugs at all. Then have your prescriber submit prior authorization with your BMI at the start of treatment, your weight-related conditions, and any diet and exercise program or medicines you've tried. If your plan prefers Wegovy, it may require a trial of Wegovy first. Zepbound for obstructive sleep apnea is a separate approved use that some plans, and Medicare Part D, cover even when weight loss isn't covered.
What if my GLP-1 prior authorization is denied?
You can appeal. For most job-based and Marketplace plans you have 180 days to file an internal appeal, and the plan must decide within 30 days for a drug you haven't received yet. If it still says no, you can ask for an independent external review within 4 months; standard reviews are decided within 45 days, urgent ones within 72 hours. A letter from your prescriber explaining medical necessity is the strongest support.
Will insurance cover Ozempic for prediabetes?
Rarely. No GLP-1 is FDA-approved for prediabetes alone, and plans almost always limit Ozempic to type 2 diabetes. Prediabetes can help you qualify for a weight-loss GLP-1 instead: Medicare's Bridge accepts a BMI of 27 or more with prediabetes, and many commercial plans count it as a weight-related condition.
Sources
- Medicare GLP-1 Bridge (demonstration July 1, 2026 – December 31, 2027; $50 copay; central prior authorization) — Centers for Medicare & Medicaid Services
- Medicare GLP-1 Bridge — Information for Providers (clinical eligibility criteria) — Centers for Medicare & Medicaid Services
- Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month (fact sheet) — Medicare.gov (CMS)
- Final CY 2026 Part D Redesign Program Instructions ($2,100 out-of-pocket threshold) — Centers for Medicare & Medicaid Services
- Internal appeals (180 days to file; decision within 30 days for services not yet received) — HealthCare.gov
- External review (4 months to request; standard decision within 45 days, expedited within 72 hours) — HealthCare.gov
- CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options (Zepbound returns October 1, 2026) — CVS Health (May 28, 2026)
- Weight-Loss Drug Coverage Ending for TRICARE For Life Users (effective August 31, 2025) — Military Officers Association of America
- People call GLP-1s life-changing. CT says it can't afford them. — CT Mirror (March 2025)
- WEGOVY, ZEPBOUND, OZEMPIC and MOUNJARO — FDA-approved prescribing information (indications) — U.S. National Library of Medicine (DailyMed)